The Healthy Baby Bottoms Study

Diaper Dermatitis Clinical Trial

Official title:

The Healthy Baby Bottoms Study: A Trial of Theraworx Foam Formulation for the Prevention and Treatment of Diaper Dermatitis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04101890
• Other study ID #: 12239
• Status: Terminated
• Phase: Phase 4
• Start date: March 12, 2020
• Est. completion date: January 2, 2021

Study information

• Verified date: November 2021
• Source: Children's National Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Diaper dermatitis is one of the most common dermatologic diseases affecting infants and children. The incidence is highest among those 9-12 months old and it has been reported to affect 7-50% of infants in the US. It is caused by skin exposure to a combination of several factors including: excessive moisture, topical irritants, reduced pH, friction, maceration and bacterial infection. When infants soil their diaper, diaper contents saturate the area raising the pH of the skin above the normal level of 5 or less, and leaving the area highly vulnerable to maceration from friction. Irritants in urine and feces are then able to penetrate the macerated skin, causing inflammation and greater skin friability. An elevation in the skin pH allows pathogenic bacteria to overgrow, and combined with the breakdown in the skin's outer epithelial barrier, can lead to bacterial infection. Theraworx Foam Formulation-Allantoin Liquid by Avadim Technologies, Inc. is a skin protectant with use for temporary protection of minor cuts, scrapes, burns and chapped or cracked skin. As such, Theraworx Foam used in the diaper area may be beneficial for protecting skin against diaper rash wounds, as well as for assisting with wound healing and reducing any associated pain. The purpose of this study is to determine caregivers' perceptions of the benefits of using Theraworx Foam on their infant's diaper area as part of their hygienic routine, including whether they feel the product is pleasant and easy to use, and whether they feel it helps prevent and reduce the severity of diaper dermatitis in their infants 1-14 months old.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: January 2, 2021
• Est. primary completion date: January 2, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Read English at the 8th grade level

• Have reliable access to email for 7 weeks

• Complete the first online survey within 24 hours of the request

• Custodial guardian of an infant between the ages of 1-12 months old living with him/her, wearing diapers, and has had =1 diaper rash in the 2 months preceding recruitment

Exclusion Criteria:

• Does not have a stable address at which to receive a package of Theraworx and is unable/unwilling to pick it up at Children's National Health System

• Infant is immunocompromised, has a congenital disorder, or on the day of recruitment, has a diaper rash, has a moderate to severe illness requiring hospitalization or transfer to the emergency room, or was circumcised <10 days prior.

Related Conditions & MeSH terms

• Dermatitis
• Diaper Dermatitis
• Diaper Rash

Intervention

Drug:
• Diaper care with Theraworx
Theraworx foam formulation to be used as a preventive and treatment agent for diaper rashes

Locations

Country	Name	City	State
United States	Chidlren's National Hospital	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
Linda Fu	Avadim Technologies, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Caregiver's Self-report of Prevention of Diaper Dermatitis in Infant	Caregivers self-report on a weekly basis the total number of days during the past week that their infant had a diaper rash. Diaper rash was defined as the presence of one or more of the following in the diaper region: redness, skin breakdown, papules or pustules. The total number of days with diaper rash for the entire 4 week period was summed from the 4 weekly surveys (outcome measure range: 0-28 days with fewer days representing a better outcome).	4 weeks
Secondary	Caregiver's Self-report of Diaper Rash Severity	Caregivers used a modified Diaper Dermatitis Scale (Buckley, et al, Pediatric Dermatology 2016) to report infant diaper rash severity. The scale ranged from 0 (none) to 6 (most severe) with higher scores indicating a worse outcome. Items on the scale included assessments of rash size (0-2), redness (0-1), evidence of skin breakdown (0-1), evidence of papules (0-1) and evidence of pustules (0-1). Mean score was calculated using scores for every day over 28 days.	4 weeks